Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

February 28, 2013

Study Completion Date

April 30, 2014

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab

IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.

DRUG

PF03512676

Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.

OTHER

Correlative Studies

Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18.

Trial Locations (1)

43210

The Ohio State University Wexner Medical Center, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Bhuvaneswari Ramaswamy

OTHER

NCT00824733 - Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter